ONC Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Oncolytics Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.40 |
| 52 Week High | CA$2.32 |
| 52 Week Low | CA$1.15 |
| Beta | 1.51 |
| 11 Month Change | -20.45% |
| 3 Month Change | 8.11% |
| 1 Year Change | -36.36% |
| 33 Year Change | -40.68% |
| 5 Year Change | -5.41% |
| Change since IPO | -90.18% |
Recent News & Updates
Recent updates
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Feb 23
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Jul 07Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?
Mar 24Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?
Dec 09We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate
Aug 25Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
May 12We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Dec 02We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth
Aug 05Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth
Apr 15We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully
Dec 31Shareholder Returns
| ONC | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -4.8% | -8.5% | 0.7% |
| 1Y | -36.4% | 1.5% | 21.7% |
Return vs Industry: ONC underperformed the Canadian Biotechs industry which returned -0.4% over the past year.
Return vs Market: ONC underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
| ONC volatility | |
|---|---|
| ONC Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: ONC has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: ONC's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 29 | Wayne Pisano | www.oncolyticsbiotech.com |
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG.
Oncolytics Biotech Inc. Fundamentals Summary
| ONC fundamental statistics | |
|---|---|
| Market cap | CA$114.07m |
| Earnings (TTM) | -CA$27.64m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.9x
P/E RatioIs ONC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONC income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$27.64m |
| Earnings | -CA$27.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ONC perform over the long term?
See historical performance and comparison